Id: acc1537
Group: 2sens
Protein: PDGFRB
Gene Symbol: PDGFRB
Protein Id: P09619
Protein Name: PGFRB_HUMAN
PTM: phosphorylation
Site: Tyr751
Site Sequence: DMSKDESVDYVPMLDMKGDVK
Disease Category: Cancer
Disease: Glioblastoma
Disease Subtype:
Disease Cellline: A172
Disease Info:
Drug: EGCG
Drug Info: "EGCG (Epigallocatechin gallate) is a polyphenolic compound primarily found in green tea, recognized for its potent antioxidant and anti-inflammatory properties, and approved by the FDA as the main ingredient in the prescription drug Veregen? (sinecatechins) for topical treatment of genital warts caused by human papillomavirus. "
Effect: modulate
Effect Info: The drug inhibited human glioblastoma cells by suppressing PDGF-Rbeta tyrosine phosphorylation and its downstream signaling pathways.
Note: site unclear
Score: 4.0
Pubmed(PMID): 10198059
Sentence Index:
Sentence:

Sequence & Structure:

MRLPGAMPALALKGELLLLSLLLLLEPQISQGLVVTPPGPELVLNVSSTFVLTCSGSAPVVWERMSQEPPQEMAKAQDGTFSSVLTLTNLTGLDTGEYFCTHNDSRGLETDERKRLYIFVPDPTVGFLPNDAEELFIFLTEITEITIPCRVTDPQLVVTLHEKKGDVALPVPYDHQRGFSGIFEDRSYICKTTIGDREVDSDAYYVYRLQVSSINVSVNAVQTVVRQGENITLMCIVIGNEVVNFEWTYPRKESGRLVEPVTDFLLDMPYHIRSILHIPSAELEDSGTYTCNVTESVNDHQDEKAINITVVESGYVRLLGEVGTLQFAELHRSRTLQVVFEAYPPPTVLWFKDNRTLGDSSAGEIALSTRNVSETRYVSELTLVRVKVAEAGHYTMRAFHEDAEVQLSFQLQINVPVRVLELSESHPDSGEQTVRCRGRGMPQPNIIWSACRDLKRCPRELPPTLLGNSSEEESQLETNVTYWEEEQEFEVVSTLRLQHVDRPLSVRCTLRNAVGQDTQEVIVVPHSLPFKVVVISAILALVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYDSTWELPRDQLVLGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSHLGPHLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSAELYSNALPVGLPLPSHVSLTGESDGGYMDMSKDESVDYVPMLDMKGDVKYADIESSNYMAPYDNYVPSAPERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLICEGKLVKICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLGGTPYPELPMNEQFYNAIKRGYRMAQPAHASDEIYEIMQKCWEEKFEIRPPFSQLVLLLERLLGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEGDNDYIIPLPDPKPEVADEGPLEGSPSLASSTLNEVNTSSTISCDSPLEPQDEPEPEPQLELQVEPEPELEQLPDSGCPAPRAEAEDSFL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
PDGFRB MIDOSTAURIN Platelet-derived growth factor receptor inhibitor 4 - acute myeloid leukemia FDA
PDGFRB DASATINIB Platelet-derived growth factor receptor beta inhibitor 4 - acute lymphoblastic leukemia DailyMed
DailyMed
PDGFRB DASATINIB Platelet-derived growth factor receptor beta inhibitor 4 Unknown status acute lymphoblastic leukemia ClinicalTrials
PDGFRB DASATINIB Platelet-derived growth factor receptor beta inhibitor 4 Completed chronic myelogenous leukemia ClinicalTrials
ClinicalTrials
PDGFRB IMATINIB MESYLATE Platelet-derived growth factor receptor beta inhibitor 4 - chronic myelogenous leukemia DailyMed
DailyMed
PDGFRB DASATINIB Platelet-derived growth factor receptor beta inhibitor 4 - chronic myelogenous leukemia DailyMed
DailyMed
PDGFRB DASATINIB Platelet-derived growth factor receptor beta inhibitor 4 Recruiting chronic myelogenous leukemia ClinicalTrials
ClinicalTrials
ClinicalTrials
PDGFRB DASATINIB Platelet-derived growth factor receptor beta inhibitor 4 Unknown status chronic myelogenous leukemia ClinicalTrials
PDGFRB IMATINIB MESYLATE Platelet-derived growth factor receptor beta inhibitor 4 Completed chronic myelogenous leukemia ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
PDGFRB REGORAFENIB Platelet-derived growth factor receptor inhibitor 4 - neoplasm ATC
PDGFRB SUNITINIB Platelet-derived growth factor receptor inhibitor 4 - neoplasm ATC
PDGFRB DASATINIB Platelet-derived growth factor receptor beta inhibitor 4 - neoplasm ATC
PDGFRB MASITINIB Platelet-derived growth factor receptor inhibitor 4 - neoplasm ATC
PDGFRB TIVOZANIB HYDROCHLORIDE Platelet-derived growth factor receptor beta inhibitor 4 - renal cell carcinoma DailyMed
FDA
PDGFRB SUNITINIB Platelet-derived growth factor receptor inhibitor 4 Completed neoplasm ClinicalTrials
PDGFRB SUNITINIB Platelet-derived growth factor receptor inhibitor 4 - renal cell carcinoma DailyMed
EMA
PDGFRB SUNITINIB Platelet-derived growth factor receptor inhibitor 4 Completed renal cell carcinoma ClinicalTrials
ClinicalTrials
PDGFRB MIDOSTAURIN Platelet-derived growth factor receptor inhibitor 4 - neoplasm ATC
PDGFRB SORAFENIB TOSYLATE Platelet-derived growth factor receptor beta inhibitor 4 - renal cell carcinoma DailyMed
PDGFRB SUNITINIB MALATE Platelet-derived growth factor receptor inhibitor 4 - renal cell carcinoma DailyMed
PDGFRB PAZOPANIB HYDROCHLORIDE Platelet-derived growth factor receptor inhibitor 4 - renal cell carcinoma FDA
DailyMed
PDGFRB SUNITINIB MALATE Platelet-derived growth factor receptor inhibitor 4 Completed renal cell carcinoma ClinicalTrials
PDGFRB PAZOPANIB HYDROCHLORIDE Platelet-derived growth factor receptor inhibitor 4 - sarcoma DailyMed
FDA
PDGFRB NINTEDANIB ESYLATE Platelet-derived growth factor receptor inhibitor 4 - systemic scleroderma DailyMed
PDGFRB SUNITINIB Platelet-derived growth factor receptor inhibitor 4 Terminated renal cell carcinoma ClinicalTrials
ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
PDGFRB-Tyr751
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: